Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Cancer Pain Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Cancer Pain Overview | 13 | 1 |
| Pipeline Products for Cancer Pain Comparative Analysis | 14 | 1 |
| Cancer Pain Therapeutics under Development by Companies | 15 | 2 |
| Cancer Pain Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Cancer Pain Pipeline Products Glance | 18 | 4 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Unknown Stage Products | 21 | 1 |
| Cancer Pain Products under Development by Companies | 22 | 3 |
| Cancer Pain Products under Investigation by Universities/Institutes | 25 | 1 |
| Cancer Pain Companies Involved in Therapeutics Development | 26 | 34 |
| Alexza Pharmaceuticals Inc | 26 | 1 |
| AngioChem Inc | 27 | 1 |
| Aoxing Pharmaceutical Company Inc | 28 | 1 |
| Aphios Corp | 29 | 1 |
| AstraZeneca Plc | 30 | 1 |
| Benitec Biopharma Ltd | 31 | 1 |
| BioDelivery Sciences International Inc | 32 | 1 |
| ChironWells GmbH | 33 | 1 |
| Colby Pharmaceutical Company | 34 | 1 |
| Daiichi Sankyo Company Ltd | 35 | 1 |
| Dompe Farmaceutici SpA | 36 | 1 |
| Fujimoto Pharmaceutical Corp | 37 | 1 |
| Grunenthal GmbH | 38 | 1 |
| GW Pharmaceuticals Plc | 39 | 1 |
| Hisamitsu Pharmaceutical Co Inc | 40 | 1 |
| Immupharma Plc | 41 | 1 |
| IntelGenx Corp | 42 | 1 |
| iX Biopharma Ltd | 43 | 1 |
| Kancera AB | 44 | 1 |
| Klaria Pharma Holding AB | 45 | 1 |
| Komipharm International Co Ltd | 46 | 1 |
| KPI Therapeutics Inc | 47 | 1 |
| Neurocentrx Pharma Ltd | 48 | 1 |
| Nippon Kayaku Co Ltd | 49 | 1 |
| Orion Oyj | 50 | 1 |
| Pain Therapeutics Inc | 51 | 1 |
| Pfizer Inc | 52 | 1 |
| Pharmaleads SA | 53 | 1 |
| Recordati SpA | 54 | 1 |
| Ribomic Inc. | 55 | 1 |
| Trillium Therapeutics Inc | 56 | 1 |
| Virobay Inc | 57 | 1 |
| WEX Pharmaceuticals Inc | 58 | 1 |
| Zynerba Pharmaceuticals Inc | 59 | 1 |
| Cancer Pain Therapeutics Assessment | 60 | 11 |
| Assessment by Monotherapy Products | 60 | 1 |
| Assessment by Target | 61 | 3 |
| Assessment by Mechanism of Action | 64 | 3 |
| Assessment by Route of Administration | 67 | 2 |
| Assessment by Molecule Type | 69 | 2 |
| Drug Profiles | 71 | 70 |
| ANG-2002 Drug Profile | 71 | 1 |
| AQU-118 Drug Profile | 72 | 1 |
| AZD-8797 Drug Profile | 73 | 2 |
| BBI-11008 Drug Profile | 75 | 1 |
| buprenorphine hydrochloride Drug Profile | 76 | 1 |
| cebranopadol Drug Profile | 77 | 3 |
| CPC-111 Drug Profile | 80 | 1 |
| crotalphine Drug Profile | 81 | 1 |
| CSTI-200 Drug Profile | 82 | 1 |
| dexmedetomidine hydrochloride Drug Profile | 83 | 2 |
| dronabinol Drug Profile | 85 | 1 |
| Drug 1 for Migraine and Cancer Pain Drug Profile | 86 | 1 |
| Drug 2 for Migraine and Cancer Pain Drug Profile | 87 | 1 |
| Drug 3 for Migraine and Cancer Pain Drug Profile | 88 | 1 |
| Drug for Cancer Neuropathic Pain Drug Profile | 89 | 1 |
| Drug for Migraine and Cancer Pain Drug Profile | 90 | 1 |
| fentanyl Drug Profile | 91 | 1 |
| fentanyl citrate Drug Profile | 92 | 2 |
| fentanyl citrate Drug Profile | 94 | 1 |
| fentanyl citrate Drug Profile | 95 | 1 |
| fentanyl citrate ER Drug Profile | 96 | 1 |
| gabapentin Drug Profile | 97 | 1 |
| HP-3150 Drug Profile | 98 | 1 |
| HS-198 Drug Profile | 99 | 1 |
| hydromorphone hydrochloride Drug Profile | 100 | 1 |
| HYLP-002 Drug Profile | 101 | 1 |
| INT-0010 Drug Profile | 102 | 1 |
| IPP-102199 Drug Profile | 103 | 1 |
| methadone hydrochloride Drug Profile | 104 | 1 |
| nabiximols Drug Profile | 105 | 7 |
| Nervarna Drug Profile | 112 | 1 |
| PAX-1 Drug Profile | 113 | 1 |
| Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain Drug Profile | 114 | 1 |
| Peptide to Target CANP for Cardiovasclar and Cancer Pain Drug Profile | 115 | 1 |
| PL-265 Drug Profile | 116 | 1 |
| QX-314 Drug Profile | 117 | 1 |
| RBM-004 Drug Profile | 118 | 1 |
| RBM-007 Drug Profile | 119 | 1 |
| resiniferatoxin Drug Profile | 120 | 2 |
| saracatinib difumarate Drug Profile | 122 | 2 |
| Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 124 | 1 |
| Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 125 | 1 |
| Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 126 | 1 |
| Small Molecules for Pancreatic Cancer and Perineural Invasion Drug Profile | 127 | 1 |
| tanezumab Drug Profile | 128 | 3 |
| Tetrodotoxin Drug Profile | 131 | 2 |
| tilidine hydrochloride Drug Profile | 133 | 1 |
| U-2902 Drug Profile | 134 | 2 |
| VBY-825 Drug Profile | 136 | 1 |
| zucapsaicin Drug Profile | 137 | 2 |
| ZYN-001 Drug Profile | 139 | 2 |
| Cancer Pain Dormant Projects | 141 | 4 |
| Cancer Pain Discontinued Products | 145 | 1 |
| Cancer Pain Product Development Milestones | 146 | 10 |
| Featured News &Press Releases | 146 | 1 |
| Sep 30, 2016: Grunenthal s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain | 146 | 1 |
| Mar 31, 2016: Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride | 146 | 1 |
| Oct 27, 2015: GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex Phase 3 Cancer Pain Trials | 147 | 1 |
| Sep 08, 2015: Kancera evaluates immuno-oncology drug candidate | 148 | 1 |
| Aug 13, 2015: Biodelivery Sciences Announces FDA Approval Of New Formulation Of Onsolis (Fentanyl Buccal Soluble Film) CII | 149 | 1 |
| Jan 27, 2015: BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda | 150 | 1 |
| Apr 28, 2014: Hospira Files Petition Against Aurobindo Over Patent Infringement | 150 | 1 |
| Apr 28, 2014: GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain | 151 | 1 |
| Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation | 151 | 1 |
| Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex | 152 | 1 |
| Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan | 152 | 1 |
| Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation | 153 | 1 |
| Feb 14, 2013: US Federal Court Validates Cephalon s Fentora Patents | 153 | 1 |
| Oct 15, 2012: BioDelivery Sciences Announces Launch Of Breakyl In EU | 154 | 1 |
| Jul 11, 2012: Taiho And Teikoku Form Business Partnership For Pain Reliever OVF | 154 | 2 |
| Appendix | 156 | 2 |
| Methodology | 156 | 1 |
| Coverage | 156 | 1 |
| Secondary Research | 156 | 1 |
| Primary Research | 156 | 1 |
| Expert Panel Validation | 156 | 1 |
| Contact Us | 156 | 1 |
| Disclaimer | 157 | 1 |